New combo aims to revive immunotherapy in resistant cancers
Disease control
Recruiting now
This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC